leflunomid gebro 100 mg compresse rivestite con film
gebro pharma ag - leflunomidum - compresse rivestite con film - leflunomidum 100 mg, excipiens pro compresso haze. - aktive rheumatoide artrite - synthetika
odomzo 200 mg capsule rigide
sun pharma switzerland ltd - sonidegibum - capsule rigide - sonidegibum 200 mg ut sonidegibi diphosphas, crospovidonum, lactosum monohydricum 38.60 mg, poloxamerum 188, natrii laurilsulfas corresp. natrium 0.605 mg, magnesii stearas, silica colloidalis anhydrica, kapselhülle: gelatina, e 171, e 172 (rubrum), drucktinte: lacca, e 172 (nigrum), propylenglycolum q.s., pro capsula. - carcinoma a cellule basali - synthetika
sivextro 200 mg compresse rivestite con film
msd merck sharp & dohme ag - tedizolidi phosphas - compresse rivestite con film - tedizolidi phosphas 200 mg, excipiens pro compresso obducto. - malattie infettive - synthetika
mvasi 100 mg/4 ml concentrato per soluzione per infusione
amgen switzerland ag - bevacizumabum - concentrato per soluzione per infusione - bevacizumabum 100 mg, trehalosum dihydricum, natrii dihydrogenophosphas monohydricus, dinatrii phosphas, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 4 ml corresp. natrium 5.42 mg. - onkologikum - biotechnologika
mvasi 400 mg/16 ml concentrato per soluzione per infusione
amgen switzerland ag - bevacizumabum - concentrato per soluzione per infusione - bevacizumabum 400 mg, trehalosum dihydricum, natrii dihydrogenophosphas monohydricus, dinatrii phosphas, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 16 ml corresp. natrium 21.68 mg. - onkologikum - biotechnologika
zirabev 100 mg/4 ml concentrato per soluzione per infusione
pfizer ag - bevacizumabum - concentrato per soluzione per infusione - bevacizumabum 100 mg, acidum succinicum, saccharum, dinatrii edetas, polysorbatum 80, natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 4 ml corresp. natrium 2.32 mg. - onkologikum - biotechnologika
zirabev 400 mg/16 ml concentrato per soluzione per infusione
pfizer ag - bevacizumabum - concentrato per soluzione per infusione - bevacizumabum 400 mg, acidum succinicum, saccharum, dinatrii edetas, polysorbatum 80, natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 16 ml corresp. natrium 9.29 mg. - onkologikum - biotechnologika
rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - agenti antineoplastici - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.
lumeblue (previously known as methylthioninium chloride cosmo)
alfasigma s.p.a. - cloruro di metiltioninio - colorectal neoplasms; colonoscopy - other diagnostic agents - lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.
rozlytrek 100 mg capsule rigide
roche pharma (schweiz) ag - entrectinibum - capsule rigide - entrectinibum 100 mg, lactosum 65 mg, cellulosum microcristallinum, acidum tartaricum, hypromellosum, crospovidonum, magnesii stearas, silica colloidalis anhydrica, kapselhülle: hypromellosum, e 171, e 172 (flavum), drucktinte: lacca, propylenglycolum, ammoniae solutio concentrata, e 132, pro capsula. - solide tumoren, nicht-kleinzelliges bronchialkarzinom (nsclc) - synthetika